Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA binding region (RNP1, RRM) containing 3 (RNPC3)
- Target
- RNPC3
- Molecular classification
- Spliceosomal protein (component of minor spliceosome), RNA-binding protein (contains RNA recognition motifs; RRM), Other: RNA processing factor
01
Overview
RNA binding region (RNP1, RRM) containing 3 (RNPC3) is a protein component of the minor spliceosome, which specifically catalyzes the removal of U12-type introns from pre-mRNA, a process required for the maturation of specific mRNA transcripts. RNPC3 contains two RNA recognition motifs, allowing it to bind U12 snRNA and promote the formation of the U11/U12 ribonucleoprotein complex. It has been identified as an autoantigen in certain autoimmune diseases, notably systemic sclerosis and mixed connective tissue disease, and anti-RNPC3 autoantibodies can serve as biomarkers for disease subset stratification and risk for organ involvement or cancer
- Other names
- RNPC3RNA binding region containing 3RNP1-containing protein 3
02
Mechanism of action
not applicable; no known drugs act directly on RNPC3 or modulate its action
03
Biological functions
Pre-mRNA splicing (specifically U12-dependent/minor spliceosome pathway)RNA binding (binds 3'-stem-loop of U12 snRNA)Molecular bridging in U11/U12 RNP complex formationRegulation of gene expression at RNA level
04
Disease associations
Pituitary hormone deficiency, isolated or combinedScleroderma/systemic sclerosis (as an autoantigen/biomarker)Mixed connective tissue disease (systemic sclerosis skin involvement, interstitial lung disease, severe gastrointestinal disease, cancer association as biomarker)
05
Safety considerations
Not directly applicable (RNPC3 is not known to be a current drug target); however, autoimmunity against RNPC3 is associated with disease states (e.g., scleroderma, interstitial lung disease)
06
Biomarkers
Anti-RNPC3 autoantibodies (used as biomarkers in subsets of scleroderma and mixed connective tissue disease, associated with risk for certain organ complications and cancer)
Beyond the preview
Go deeper on RNA binding region (RNP1, RRM) containing 3 (RNPC3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNA binding region (RNP1, RRM) containing 3 (RNPC3).